Millipore Sigma Vibrant Logo

521275 PDK1/Akt/Flt Dual Pathway Inhibitor - CAS 331253-86-2 - Calbiochem

Übersicht

Replacement Information

Key Spec Table

CAS #Empirical Formula
331253-86-2C₁₀H₄N₆O

Preis & Verfügbarkeit

Bestellnummer VerfügbarkeitVerpackung St./Pkg. Preis Menge
521275-5MG
Verfügbarkeit wird abgerufen...
Eingeschränkte Verfügbarkeit
Eingeschränkte Verfügbarkeit
Lieferbar 
Produkt wurde eingestellt
Begrenzter Lagerbestand
Bestätigung der Verfügbarkeit erforderlich
    Restmenge: Angebot folgt
      Restmenge: Angebot folgt
      Bitte erfragen
      Kontakt zum Kundenservice
      Contact Customer Service

      Kst.-Ampulle 5 mg
      Preis wird abgerufen...
      Preis nicht abrufbar
      Die Mindestmenge muss ein Vielfaches sein von
      Maximum Quantity is
      Bei Bestätigung Weitere Informationen
      Sie haben () gespart
       
      Bitte erfragen
      Description
      OverviewA cell-permeable compound that selectively induces apoptosis in AML (Acute Myelogenous Leukemia) with little effect on normal CD34+ AML progenitor cells. Shown to directly inhibit both PDK1 and Akt activities in in vitro kinase assays in a dose-dependent manner and block cellular phosphorylation of Akt at both Ser473 and Thr308. The dual inhibition nature against both PDK1/Akt and Flt3/PIM signaling pathways allows effective killing of AML cells (Average IC50 = 1.05, 1.91, and 0.43 µM for AML with wild-type Flt3, single mutant ITD/D835, and double mutant Flt3-ITD-TDK, respectively) that are otherwise resistant to inhibitors that target only the PDK1/Akt pathway.
      CAS. Nos. 331253-86-2 and 329710-24-9 (two isomers)
      Catalogue Number521275
      Brand Family Calbiochem®
      Synonyms6H-Indeno[1,2-e]tetrazolo[1,5-b][1,2,4]triazin-6-one & 10H-Indeno[2,1-e]tetrazolo[1,5-b][1,2,4]triazin-10-one, Akt Inhibitor XXI, PDK1 Inhibitor I, KP372-1
      References
      ReferencesZeng, Z., et al. 2006. Cancer Res. 66, 3737.
      Koul, D., et al. 2006. Mol. Cancer Ther. 5, 637.
      Mandal. M., et al. 2006. Oral Oncol. 42, 430.
      Mandal. M., et al. 2005. Br. J. Cancer 92, 1899.
      Product Information
      CAS number331253-86-2
      ATP CompetitiveN
      FormYellow solid
      Hill FormulaC₁₀H₄N₆O
      Chemical formulaC₁₀H₄N₆O
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetBoth PDK1 and Akt activities
      Primary Target IC<sub>50</sub>1.05, 1.91, and 0.43 µM for AML with wild-type Flt3, single mutant ITD/D835, and double mutant Flt3-ITD-TDK, respectively
      Purity≥98% by HPLC (sum of two isomers)
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      R PhraseR: 36/37/38

      Irritating to eyes, respiratory system and skin.
      S PhraseS: 26-36

      In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
      Wear suitable protective clothing.
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Irritant
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Bestellnummer GTIN
      521275-5MG 04055977271447

      Documentation

      PDK1/Akt/Flt Dual Pathway Inhibitor - CAS 331253-86-2 - Calbiochem SDB

      Titel

      Sicherheitsdatenblatt (SDB) 

      PDK1/Akt/Flt Dual Pathway Inhibitor - CAS 331253-86-2 - Calbiochem Analysenzertifikate

      TitelChargennummer
      521275

      Literatur

      Übersicht
      Zeng, Z., et al. 2006. Cancer Res. 66, 3737.
      Koul, D., et al. 2006. Mol. Cancer Ther. 5, 637.
      Mandal. M., et al. 2006. Oral Oncol. 42, 430.
      Mandal. M., et al. 2005. Br. J. Cancer 92, 1899.

      Broschüre

      Titel
      Akt

      Posters

      Titel
      Human Kinome & InhibitorSelect™ Libraries
      Datenblatt

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision18-April-2011 RFH
      Synonyms6H-Indeno[1,2-e]tetrazolo[1,5-b][1,2,4]triazin-6-one & 10H-Indeno[2,1-e]tetrazolo[1,5-b][1,2,4]triazin-10-one, Akt Inhibitor XXI, PDK1 Inhibitor I, KP372-1
      DescriptionA cell-permeable compound that selectively induces apoptosis in AML (Acute Myelogenous Leukemia) with little effect on normal CD34+ AML progenitor cells. Shown to directly inhibit both PDK1 and Akt activities in in vitro kinase assays in a dose-dependent manner and block cellular phosphorylation of Akt at both Ser473 and Thr308. The dual inhibition nature against both PDK1/Akt and Flt3/PIM signaling pathways allows effective killing of AML cells (Average IC50 = 1.05, 1.91, and 0.43 µM for AML with wild-type Flt3, single mutant ITD/D835, and double mutant Flt3-ITD-TDK, respectively) that are otherwise resistant to inhibitors that target only the PDK1/Akt pathway. CAS. No. 331253-86-2 and 329710-24-9.
      FormYellow solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number331253-86-2
      Chemical formulaC₁₀H₄N₆O
      Structure formulaStructure formula
      Purity≥98% by HPLC (sum of two isomers)
      SolubilityDMSO (10 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Irritant
      ReferencesZeng, Z., et al. 2006. Cancer Res. 66, 3737.
      Koul, D., et al. 2006. Mol. Cancer Ther. 5, 637.
      Mandal. M., et al. 2006. Oral Oncol. 42, 430.
      Mandal. M., et al. 2005. Br. J. Cancer 92, 1899.